Asset Details
Do you wish to reserve the book?
Prognostic value of baseline 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prognostic value of baseline 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy
Do you wish to request the book?
Prognostic value of baseline 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prognostic value of baseline 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy
2023
Overview
Purpose
To investigate the prognostic value of baseline
18
F-FDG PET/CT in patients with esophageal squamous cell carcinoma (ESCC) treated with definitive (chemo)radiotherapy.
Methods
A total of 98 ESCC patients with cTNM stage T1-4, N1-3, M0 who received definitive (chemo)radiotherapy after
18
F-FDG PET/CT examination from December 2013 to December 2020 were retrospectively analyzed. Clinical factors included age, sex, histologic differentiation grade, tumor location, clinical stage, and treatment strategies. Parameters obtained by
18
F-FDG PET/CT included SUV
max
of primary tumor (SUV
Tumor
), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUV
max
of lymph node (SUV
LN
), PET positive lymph nodes (PLNS) number, the shortest distance between the farthest PET positive lymph node and the primary tumor in three-dimensional space after the standardization of the patient BSA (SD
max(LN-T)
). Univariate and multivariate analysis was conducted by Cox proportional hazard model to explore the significant factors affecting overall survival (OS) and progression-free survival (PFS) in ESCC patients.
Results
Univariate analysis showed that tumor location, SUV
Tumor
, MTV, TLG, PLNS number, SD
max (LN-T)
were significant predictors of OS and tumor location, and clinical T stage, SUV
Tumor
, MTV, TLG, SD
max (LN-T)
were significant predictors of PFS (all
p
< 0.1). Multivariate analysis showed that MTV and SD
max (LN-T)
were independent prognostic factors for OS (HR = 1.018, 95% CI 1.006–1.031;
p
= 0.005; HR = 6.988, 95% CI 2.119–23.042;
p
= 0.001) and PFS (HR = 1.019, 95% CI 1.005–1.034;
p
= 0.009; HR = 5.819, 95% CI 1.921–17.628;
p
= 0.002). Combined with independent prognostic factors MTV and SD
max (LN-T)
, we can further stratify patient risk.
Conclusions
Before treatment,
18
F-FDG PET/CT has important prognostic value for patients with ESCC treated with definitive (chemo)radiotherapy. The lower the value of MTV and SD
max (LN-T)
, the better the prognosis of patients.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
